Five Prime Therapeutics, Inc.

Justin Wong

Maximiliano Vasquez

Kevin Hestir

Lewis T Williams

Stephen Kohl Doberstein

Diane Hollenbaugh

Ernestine A Lee

Minmin Qin

Hongbing Zhang

Elizabeth Bosch

Ali Sadra

Ge Wu

Brian Wong

Emma Masteller

Haishan Lin

Antibodies that bind CSF1R are provided. Antibody heavy chains and light chains that are capable of forming antibodies that bind CSF1R are also provided. Polynucleotides encoding antibodies to CSF1R are provided. Polynucleotides encoding antibody heavy chains and lights chains are also provided. Methods of treatment using antibodies to CSF1R are provided. Such methods include, but are not limited to, methods of treating rheumatoid arthritis, bone loss, and multiple sclerosis.

Antibodies that bind colony stimulating factor 1 receptor (CSF1R)

Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R) are provided. Such methods include, but are not limited to, methods of treating rheumatoid arthritis and associated conditions, methods of treating systemic lupus erythematosus and associated conditions, and methods of treating multiple sclerosis.

Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R)

Nucleic acids encoding antibodies that bind colony stimulating factor 1 receptor (CSF1R)

The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.

Methods of treating disease with FGFR1 fusion proteins

FGFR2 fusion proteins comprising C-terminal deletion mutants of FGFR2-IIIC

Methods of treatment by administering antibodies that bind colony stimulating factor 1 receptor (CSF1R)

Polynucleotides encoding FGFR1-IIIc ECD fusion proteins

This invention relates to the polynucleotides and the encoded polypeptides, including novel sequences, of human or non-human primate genes that are amplified in breast and/or other tumor tissues melanoma, as compared to the corresponding normal tissue. The invention also relates to modulators of such polynucleotides and polypeptides, for example, antibodies, that specifically bind to and/or interfere with the activity of this polypeptide, polynucleotide, its fragments, variants, and antagonists. The invention further relates to compositions containing such a polypeptide, polynucleotide, or modulators thereof and uses of such compositions in methods of treating or preventing cancer, by detecting this polynucleotide, polypeptide, or antibodies thereto in patient samples. The invention also provides diagnostic tests for breast cancer and melanoma, by identifying polypeptides and polynucleotides encoded by the cDNA sequence of the invention that correlate with those disorders.

Compositions and methods of use for modulators of polypeptides and polynucleotides in treating breast cancer and melanoma

FGFR3-IIIc fusion proteins

Growing community of inventors

Oakland, CA, United States of America

Justin Wong